acetylcarnitine has been researched along with Ache in 24 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Excerpt | Relevance | Reference |
---|---|---|
"Thioctic acid 600 mg/day appears to be at least as effective as ALC in the treatment of sciatic pain caused by a herniated disc and may be associated with an improvement in symptom scores and reduced need for analgesia." | 9.13 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
"Prophylactic treatment with acetyl-L-carnitine (ALCAR) prevents the neuropathic pain syndrome that is evoked by the chemotherapeutic agent, paclitaxel." | 7.74 | Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. ( Bennett, GJ; Flatters, SJ; Jin, HW; Mulhern, HL; Xiao, WH, 2008) |
"This study examines the potential efficacy of acetyl-L-carnitine (ALC) to prevent and treat paclitaxel-induced pain." | 7.73 | Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. ( Bennett, GJ; Flatters, SJ; Xiao, WH, 2006) |
"Although sciatic pain is typically self-limiting, pharmacological analgesic therapy forms the mainstay of treatment." | 6.73 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
"Sciatica is a painful condition characterized by radiating leg pain that most commonly originates from a herniated disc in the lumbar or sacral spine." | 6.73 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
" Evidence from animal models of chemotherapy-induced painful peripheral neuropathy produced by the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin, indicate that they produce neuropathy via a common mechanism-a toxic effect on the mitochondria in primary afferent sensory neurons." | 5.38 | Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. ( Bennett, GJ; Xiao, WH; Zheng, H, 2012) |
"Thioctic acid 600 mg/day appears to be at least as effective as ALC in the treatment of sciatic pain caused by a herniated disc and may be associated with an improvement in symptom scores and reduced need for analgesia." | 5.13 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
"Prophylactic treatment with acetyl-L-carnitine (ALCAR) prevents the neuropathic pain syndrome that is evoked by the chemotherapeutic agent, paclitaxel." | 3.74 | Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. ( Bennett, GJ; Flatters, SJ; Jin, HW; Mulhern, HL; Xiao, WH, 2008) |
"This study examines the potential efficacy of acetyl-L-carnitine (ALC) to prevent and treat paclitaxel-induced pain." | 3.73 | Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. ( Bennett, GJ; Flatters, SJ; Xiao, WH, 2006) |
"Although sciatic pain is typically self-limiting, pharmacological analgesic therapy forms the mainstay of treatment." | 2.73 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
"Sciatica is a painful condition characterized by radiating leg pain that most commonly originates from a herniated disc in the lumbar or sacral spine." | 2.73 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
"Treatment of peripheral neuropathies is targeted to its symptomatic and aetiological features." | 2.44 | Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. ( Capiluppi, E; Mailland, E; Mariani, C; Nascimbene, C; Osio, M; Vanotti, A, 2007) |
"Peripheral neuropathies are extremely heterogeneous nosological entities." | 2.44 | Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. ( Capiluppi, E; Mailland, E; Mariani, C; Nascimbene, C; Osio, M; Vanotti, A, 2007) |
"Pancreatitis was induced with 6 hly intraperitoneal (i." | 1.62 | Effect of acetyl-L-carnitine on hypersensitivity in acute recurrent caerulein-induced pancreatitis and microglial activation along the brain's pain circuitry. ( High, AE; McIlwrath, SL; Saito, H; Starr, ME; Westlund, KN, 2021) |
"Pain was measured in animals submitted to MIA model by paw pressure and compression behavioral tests in the presence or absence of ALC." | 1.40 | Prophylactic role of acetyl-l-carnitine on knee lesions and associated pain in a rat model of osteoarthritis. ( Aglianò, M; Bianchi, E; Di Cesare Mannelli, L; Ghelardini, C; Lorenzoni, P; Menicacci, C, 2014) |
" Evidence from animal models of chemotherapy-induced painful peripheral neuropathy produced by the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin, indicate that they produce neuropathy via a common mechanism-a toxic effect on the mitochondria in primary afferent sensory neurons." | 1.38 | Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. ( Bennett, GJ; Xiao, WH; Zheng, H, 2012) |
"ALCAR completely prevented mechanical hyperalgesia and provoked in the nerve a c-Jun increment only." | 1.36 | The neuropathy-protective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. ( Bartolini, A; Di Cesare Mannelli, L; Ghelardini, C; Pacini, A; Toscano, A, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (8.33) | 18.2507 |
2000's | 9 (37.50) | 29.6817 |
2010's | 8 (33.33) | 24.3611 |
2020's | 5 (20.83) | 2.80 |
Authors | Studies |
---|---|
D'Orio, M | 1 |
De Vitis, R | 1 |
Taccardo, G | 1 |
Rocchi, L | 1 |
Ferrari, F | 1 |
Perna, A | 1 |
Passiatore, M | 1 |
Salaffi, F | 1 |
Farah, S | 1 |
Sarzi-Puttini, P | 1 |
Di Carlo, M | 1 |
Lowry, E | 1 |
Marley, J | 1 |
McVeigh, JG | 1 |
McSorley, E | 1 |
Allsopp, P | 1 |
Kerr, D | 1 |
Ardizzone, A | 1 |
Fusco, R | 1 |
Casili, G | 1 |
Lanza, M | 1 |
Impellizzeri, D | 1 |
Esposito, E | 1 |
Cuzzocrea, S | 1 |
McIlwrath, SL | 1 |
Starr, ME | 1 |
High, AE | 1 |
Saito, H | 1 |
Westlund, KN | 1 |
Sergi, G | 1 |
Pizzato, S | 1 |
Piovesan, F | 1 |
Trevisan, C | 1 |
Veronese, N | 1 |
Manzato, E | 1 |
Cruccu, G | 1 |
Di Stefano, G | 1 |
Fattapposta, F | 1 |
Jann, S | 1 |
Padua, L | 1 |
Schenone, A | 1 |
Truini, A | 1 |
Bianchi, E | 1 |
Di Cesare Mannelli, L | 3 |
Menicacci, C | 1 |
Lorenzoni, P | 1 |
Aglianò, M | 1 |
Ghelardini, C | 3 |
Traina, G | 1 |
Memeo, A | 1 |
Loiero, M | 1 |
Toscano, A | 1 |
Pacini, A | 1 |
Bartolini, A | 2 |
Chiechio, S | 3 |
Copani, A | 3 |
Zammataro, M | 1 |
Battaglia, G | 1 |
Gereau, RW | 2 |
Nicoletti, F | 3 |
Vivoli, E | 1 |
Salvicchi, A | 1 |
Koverech, A | 1 |
Nicolai, R | 2 |
Benatti, P | 1 |
Zheng, H | 1 |
Xiao, WH | 3 |
Bennett, GJ | 3 |
Melchiorri, D | 1 |
Canudas, AM | 1 |
Storto, M | 1 |
Calvani, M | 2 |
Sima, AA | 1 |
Mehra, M | 1 |
Amato, A | 1 |
Flatters, SJ | 2 |
Osio, M | 3 |
Muscia, F | 1 |
Zampini, L | 1 |
Nascimbene, C | 2 |
Mailland, E | 2 |
Cargnel, A | 1 |
Mariani, C | 2 |
Youle, M | 1 |
Vanotti, A | 1 |
Capiluppi, E | 1 |
Jin, HW | 1 |
Mulhern, HL | 1 |
Onofrj, M | 1 |
Fulgente, T | 1 |
Melchionda, D | 1 |
Marchionni, A | 1 |
Tomasello, F | 1 |
Salpietro, FM | 1 |
Alafaci, C | 1 |
De Sanctis, E | 1 |
Pennisi, G | 1 |
Bella, R | 1 |
Scarpini, E | 1 |
Sacilotto, G | 1 |
Baron, P | 1 |
Cusini, M | 1 |
Scarlato, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Microbiome Correlates of Dietary Interventions in Patients With Fibromyalgia and Their Association With Symptom Modification[NCT05329571] | 50 participants (Anticipated) | Interventional | 2021-03-12 | Active, not recruiting | |||
Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial.[NCT02141035] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
An Open-Label, Dose-Escalation Pilot Study of Acetyl-L-Carnitine for the Treatment of Dideoxynucleoside-Associated Distal Symmetric Peripheral Neuropathy[NCT00050271] | 27 participants (Actual) | Interventional | Completed | ||||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
6 reviews available for acetylcarnitine and Ache
Article | Year |
---|---|
Dietary Interventions in the Management of Fibromyalgia: A Systematic Review and Best-Evidence Synthesis.
Topics: Acetylcarnitine; Ascorbic Acid; Chlorella; Diet, Vegan; Dietary Supplements; Fermented Foods; Fibrom | 2020 |
Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders.
Topics: Acetylcarnitine; Aged; Alzheimer Disease; Analgesics; Diabetic Neuropathies; Humans; Mitochondria; P | 2018 |
The neurobiology of acetyl-L-carnitine.
Topics: Acetylcarnitine; Aging; Animals; Apoptosis; Brain; Dietary Supplements; Energy Metabolism; Epigenesi | 2016 |
Metabotropic receptors as targets for drugs of potential use in the treatment of neuropathic pain.
Topics: Acetylcarnitine; Analgesics; Animals; Humans; Nootropic Agents; Pain; Peripheral Nervous System Dise | 2004 |
Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies.
Topics: Acetylcarnitine; Analgesics, Opioid; Animals; Anticonvulsants; Antidepressive Agents; Antineoplastic | 2007 |
Acetyl-L-carnitine in neuropathic pain: experimental data.
Topics: Acetylcarnitine; Analgesia; Animals; Humans; Nootropic Agents; Pain; Peripheral Nervous System Disea | 2007 |
8 trials available for acetylcarnitine and Ache
Article | Year |
---|---|
Clinical usefulness of nutraceutics with acetyl-L-carnitine, α-lipoic acid, phosphatidylserine, curcumin, C, E and B-group vitamins in patients awaiting for carpal tunnel release during COVID-19 pandemic: a randomized controlled open label prospective stu
Topics: Acetylcarnitine; Carpal Tunnel Syndrome; COVID-19; Curcumin; Humans; Pain; Pandemics; Phosphatidylse | 2023 |
Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study.
Topics: Acetylcarnitine; Analgesics; Duloxetine Hydrochloride; Fibromyalgia; Humans; Pain; Pregabalin; Treat | 2023 |
Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Analgesics; Antioxidants; Double-Blind Method; Elec | 2008 |
Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials.
Topics: Acetylcarnitine; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Human | 2005 |
Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study.
Topics: Acetylcarnitine; Adult; Aged; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Middle | 2006 |
A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection.
Topics: Acetylcarnitine; Administration, Oral; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infe | 2007 |
L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain.
Topics: Acetylcarnitine; Adolescent; Adult; Aged; Double-Blind Method; Humans; Injections, Intramuscular; Mi | 1995 |
Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients.
Topics: Acetylcarnitine; Adult; Female; HIV Seropositivity; Humans; Male; Middle Aged; Nootropic Agents; Pai | 1997 |
10 other studies available for acetylcarnitine and Ache
Article | Year |
---|---|
Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
Topics: Acetylcarnitine; Amides; Animals; Carrageenan; Cell Count; Cyclooxygenase 2; Disease Models, Animal; | 2021 |
Effect of acetyl-L-carnitine on hypersensitivity in acute recurrent caerulein-induced pancreatitis and microglial activation along the brain's pain circuitry.
Topics: Acetylcarnitine; Acute Disease; Animals; Brain; Ceruletide; Disease Models, Animal; Male; Mice; Mice | 2021 |
L-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain.
Topics: Acetylcarnitine; Adult; Analgesics; Carpal Tunnel Syndrome; Female; Humans; Male; Median Nerve; Midd | 2017 |
Prophylactic role of acetyl-l-carnitine on knee lesions and associated pain in a rat model of osteoarthritis.
Topics: Acetylcarnitine; Animals; Chondrocytes; Disease Models, Animal; Male; Osteoarthritis, Knee; Pain; Pa | 2014 |
The neuropathy-protective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain.
Topics: Acetylcarnitine; Animals; Disease Models, Animal; Enzyme Activation; Functional Laterality; Hyperalg | 2010 |
Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain.
Topics: Acetylcarnitine; Animals; Chronic Disease; Epigenesis, Genetic; Humans; Pain; Pain Management; Recep | 2010 |
Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy.
Topics: Acetylcarnitine; Analgesics; Animals; Constriction, Pathologic; Ganglia, Spinal; Male; Nerve Growth | 2010 |
Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.
Topics: Acetylcarnitine; Activating Transcription Factor 3; Adenosine Triphosphate; Analysis of Variance; An | 2012 |
Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy.
Topics: Acetylcarnitine; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Male; Paclitaxel; | 2006 |
Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells.
Topics: Acetylcarnitine; Animals; Axons; Behavior, Animal; Disease Models, Animal; Drug Interactions; Langer | 2008 |